Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis

Kuwatani, Masaki; Kawakami, Hiroshi; Kubota, Yoshimasa; Kawakubo, Kazumichi; Ito, Yoichi M.; Togo, Shinji; Ikeda, Takaaki; Kusama, Ken; Kobayashi, Yuka; Murata, Teizo; Sakamoto, Naoya

Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis

Kuwatani, Masaki; Kawakami, Hiroshi; Kubota, Yoshimasa et al.

Pancreatology, 2019, 19(4), 569-577

Permalink : https://hdl.handle.net/2115/78262

このアイテムのアクセス数:718件（2026-08-14 05:54 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Pancreatology_19_569	pdf	871 KB	651

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/78262
タイトル	Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis
著者	Kuwatani, Masaki ; Kawakami, Hiroshi ; Kubota, Yoshimasa ; Kawakubo, Kazumichi ; Ito, Yoichi M. ; Togo, Shinji ; Ikeda, Takaaki ; Kusama, Ken ; Kobayashi, Yuka ; Murata, Teizo ; Sakamoto, Naoya
e-Rad_Researcher 50431375 著者名 Kuwatani, Masaki
e-Rad_Researcher 80399823 著者名 Kawakami, Hiroshi
著者名 Kubota, Yoshimasa
著者名 Kawakubo, Kazumichi
e-Rad_Researcher 10334236 著者名 Ito, Yoichi M.
著者名 Togo, Shinji
著者名 Ikeda, Takaaki
著者名 Kusama, Ken
著者名 Kobayashi, Yuka
著者名 Murata, Teizo
e-Rad_Researcher 10334418 著者名 Sakamoto, Naoya
言語	英語
キーワード	CA19-9
	CEA
	Fucosylated haptoglobin
	Pancreatic cancer
	Lectin
発行日	2019-06
出版者	Elsevier
収録物名	Pancreatology
巻(号)	19(4)
ページ	569-577
抄録	Background: Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL) that had specificity for fucose alpha 1-6 was reported as an effective biomarker for several gastrointestinal diseases. The aim of this study was to verify Fucosylated haptoglobin detected by Pholiota squarrosa lectin (PhoSL-HP) as a pancreatic cancer (PC) marker using a new method of PhoSL-ELISA. Methods: PhoSL-HP in sera from 98 PC patients and 158 non-PC samples including 32 intraductal papillary mucinous neoplasm (IPMN) patients, 21 chronic pancreatitis (CP) patients and 105 non-pancreatic disease controls (NPDC) were measured. We compared sensitivities, specificities and areas under the curves (AUC) of PhoSL-HP, CA19-9 and CEA as single markers. We also evaluated PhoSL-HP as combination marker by comparing AUC of CA19-9 combined with PhoSL-HP or CEA. Results: The sensitivities of PhoSL-HP, CA19-9 and CEA for PC were 58%, 76% and 42%, respectively. Although the specificity of PhoSL-HP for NPDC was inferior to both of CA19-9 and CEA, that for pancreatic diseases was higher than both of CA19-9 and CEA. Combined CA19-9 with PhoSL-HP, the AUC was significantly higher at 0.880 than single use of CA19-9 at 0.825 in case of distinguishing PC from other pancreatic diseases. In contrast, the AUC of CA19-9 was not elevated significantly when combined with CEA. Conclusion: PhoSL-HP would be a useful marker for PC and have sufficient complementarity for CA19-9. (C) 2019 Published by Elsevier B.V. on behalf of IAP and EPC.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	1424-3903
関連情報	PMID 31031206
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.pan.2019.04.007